OBJECTIVES: Minimally invasive mitral valve surgery (mini-MVR) has numerous associated benefits. However, many studies fail to include greater-risk patients. We hypothesized that a minimally invasive approach in a representative cohort provides excellent outcomes with reduced resource utilization. METHODS: Mitral valve surgical records from 2011 to 2016 were paired with institutional financial records. Patients were stratified by approach and propensity-score matched to balance preoperative difference. The primary outcomes of interest were resource utilization including cost, discharge to a facility, and readmission. RESULTS: A total of 478 patients underwent mitral surgery (21% mini-MVR) and were balanced after matching (n = 74 per group), with 18% of patients having nondegenerative mitral disease. Outcomes were excellent with similar rates of major morbidity (9.5% mini-MVR vs 10.8% conventional, P = .78). Mini-MVR cases had lower rates of transfusion (11% vs 27%, P = .01) and shorter ventilator times (3.7 vs 6.0 hours, P < .0001). Mean total hospital cost was equivalent ($49,703 vs $54,970, P = .235) with mini-MVR having lower ancillary ($1645 vs $2652, P = .001) and blood costs ($383 vs $1058, P = .001). These savings were offset by longer surgical times (291 vs 234 minutes, P < .0001) with greater surgical ($7645 vs $7293, P = .0001) and implant costs ($1148 vs $748, P = .03). Rates of discharge to a facility (9.6% vs 16.2%) and readmission (9.6% vs 4.1%) were not statistically different. CONCLUSIONS: In a real-world cohort, mini-MVR continues to demonstrate excellent results with a favorable resource utilization profile. Greater surgical and implant costs with mini-MVR are offset by decreased transfusions and ancillary needs leading to equivalent overall hospital cost.
OBJECTIVES: Minimally invasive mitral valve surgery (mini-MVR) has numerous associated benefits. However, many studies fail to include greater-risk patients. We hypothesized that a minimally invasive approach in a representative cohort provides excellent outcomes with reduced resource utilization. METHODS: Mitral valve surgical records from 2011 to 2016 were paired with institutional financial records. Patients were stratified by approach and propensity-score matched to balance preoperative difference. The primary outcomes of interest were resource utilization including cost, discharge to a facility, and readmission. RESULTS: A total of 478 patients underwent mitral surgery (21% mini-MVR) and were balanced after matching (n = 74 per group), with 18% of patients having nondegenerative mitral disease. Outcomes were excellent with similar rates of major morbidity (9.5% mini-MVR vs 10.8% conventional, P = .78). Mini-MVR cases had lower rates of transfusion (11% vs 27%, P = .01) and shorter ventilator times (3.7 vs 6.0 hours, P < .0001). Mean total hospital cost was equivalent ($49,703 vs $54,970, P = .235) with mini-MVR having lower ancillary ($1645 vs $2652, P = .001) and blood costs ($383 vs $1058, P = .001). These savings were offset by longer surgical times (291 vs 234 minutes, P < .0001) with greater surgical ($7645 vs $7293, P = .0001) and implant costs ($1148 vs $748, P = .03). Rates of discharge to a facility (9.6% vs 16.2%) and readmission (9.6% vs 4.1%) were not statistically different. CONCLUSIONS: In a real-world cohort, mini-MVR continues to demonstrate excellent results with a favorable resource utilization profile. Greater surgical and implant costs with mini-MVR are offset by decreased transfusions and ancillary needs leading to equivalent overall hospital cost.
Authors: Michael R Petracek; Marzia Leacche; Natalia Solenkova; Ramanan Umakanthan; Rashid M Ahmad; Stephen K Ball; Steven J Hoff; Tarek S Absi; Jorge M Balaguer; John G Byrne Journal: Ann Surg Date: 2011-10 Impact factor: 12.969
Authors: James S Gammie; Yue Zhao; Eric D Peterson; Sean M O'Brien; J Scott Rankin; Bartley P Griffith Journal: Ann Thorac Surg Date: 2010-11 Impact factor: 4.330
Authors: Andrew B Goldstone; Pavan Atluri; Wilson Y Szeto; Alen Trubelja; Jessica L Howard; John W MacArthur; Craig Newcomb; Joseph P Donnelly; Dale M Kobrin; Mary A Sheridan; Christiana Powers; Robert C Gorman; Joseph H Gorman; Alberto Pochettino; Joseph E Bavaria; Michael A Acker; W Clark Hargrove; Y Joseph Woo Journal: J Thorac Cardiovasc Surg Date: 2013-03 Impact factor: 5.209
Authors: Arman Kilic; Joshua C Grimm; J Trent Magruder; Christopher M Sciortino; Glenn J R Whitman; William A Baumgartner; John V Conte Journal: J Thorac Cardiovasc Surg Date: 2015-02-28 Impact factor: 5.209
Authors: Kenan W Yount; James M Isbell; Casey Lichtendahl; Zachary Dietch; Gorav Ailawadi; Irving L Kron; John A Kern; Christine L Lau Journal: Ann Thorac Surg Date: 2015-07-21 Impact factor: 4.330
Authors: Emily A Downs; Lily E Johnston; Damien J LaPar; Ravi K Ghanta; Irving L Kron; Alan M Speir; Clifford E Fonner; John A Kern; Gorav Ailawadi Journal: Ann Thorac Surg Date: 2016-03-31 Impact factor: 4.330